I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Tuesday, October 23, 2012

Lapatinib-Veliparib Drug Combination As Treatment Option for Triple Negative Breast Cancer

 “If you hit triple-negative cancer cells with lapatinib, among other things, it breaks down the ability of the cell to repair its DNA,” Yang explains. “By utilizing the PARP inhibitor on top of that, the cancer cell continues to accumulate damage to its DNA, causing the cell to die. This potent combination causes an interaction that is lethal to triple-negative breast cancer cells.”

http://www.uab.edu/news/briefs/item/2841-uab-study-reveals-novel-treatment-option-for-triple-negative-breast-cancer (Click link for full story)

Total Pageviews



"click image to link"